FAKTOR-OPTIONSSCHEIN - ROCHE GS Share Price

Certificat

DE000MC69NK3

Market Closed - Börse Stuttgart 12:18:19 01/06/2024 am IST
0.047 EUR +4.44% Intraday chart for FAKTOR-OPTIONSSCHEIN - ROCHE GS
Current month+20.51%
1 month+20.51%
Date Price Change
31/24/31 0.047 +4.44%
30/24/30 0.045 -2.17%
29/24/29 0.046 -4.17%
28/24/28 0.048 +2.13%
27/24/27 0.047 -2.08%

Delayed Quote Börse Stuttgart

Last update May 01, 2024 at 12:18 am IST

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer Morgan Stanley
WKN MC69NK
ISINDE000MC69NK3
Date issued 21/02/2020
Strike 190.3 CHF
Maturity Unlimited
Parity 837.58 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 9.59
Lowest since issue 0.033

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
231 CHF
Average target price
277.5 CHF
Spread / Average Target
+20.14%
Consensus